IHS Chemical Week

Regions :: Western Europe :: Switzerland

Lonza, Teva to Form Biosimilars JV

3:09 AM MST | January 20, 2009 | Deepti Ramesh

Lonza and Teva Pharmaceutical Industries (Petah Tikva, Israel) say they have agreed to establish a joint venture to develop, manufacture and market a portfolio of biosimilars. The joint venture is expected to commence activities during the first quarter of 2009, subject to receipt of regulatory approvals. Financial details of the deal were not disclosed. The two companies will cooperate to develop, manufacture and market a number of affordable, efficacious and safe generic equivalents of a selected portfolio of biologic pharmaceuticals. “We had identified...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers




contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa